Zhongnan Medical Journal Press

Home Results

A total of 5 result was found. Results that relate to Cost-effectiveness analysis

Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2023,32(11):1259-1266.
3747 times 1095 times

Xi ZHAO Xi YAN Ning LI Chun-Xia HOU

Abemaciclib Fulvestrant Hormone receptor-positive breast cancer Markov model Cost-effectiveness analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):269-276.
3896 times 1136 times

YANG Lei WANG Fengling HUANG Ling LI Yan ZHENG Hanrui ZHENG Lingli CHEN Li

Enzalutamide Metastatic prostate cancer Markov model Cost-effectiveness analysis
Details
Research progress of equity-informative health economic evaluation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(8):929-937.
5573 times 1099 times

FANG Nan HE Xiaoning WU Jing

Economic evaluation Equity Equity-based weighting Distributional cost-effectiveness Extended cost-effectiveness analysis
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(12):1375-1381.
11177 times 591 times

SUN Zhihong ZHAO Shaoliang ZHOU Furong LIU Feiyu WANG Pengcheng ZOU Shaohua GUO Chenyu

Multi-station dispensing robot Pharmacy intravenous admixture services Dispensing efficiency Cost-effectiveness analysis Economic evaluation
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
1572 times 258 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details